International Journal of Antibiotic Research

International Journal of Antibiotic Research

International Journal of Antibiotic Research – Aim And Scope

Open Access & Peer-Reviewed

Submit Manuscript

Aims & Scope

International Journal of Antibiotic Research publishes fundamental research on the microbiology, biochemistry, and molecular mechanisms of antibiotics, antimicrobial resistance, and microbial physiology. We focus on the science of antibiotics—not clinical prescribing or patient management.
Antimicrobial Resistance Antibiotic Biosynthesis Bacterial Genetics Molecular Mechanisms Microbial Physiology
We do NOT consider: Clinical case reports, patient treatment protocols, prescribing guidelines, or infection management studies without substantial microbiological investigation.

Core Research Domains

Antimicrobial Resistance Mechanisms

  • Genetic basis of resistance (chromosomal and plasmid-mediated)
  • Horizontal gene transfer and mobile genetic elements
  • Efflux pumps and membrane permeability alterations
  • Target site modifications and enzymatic inactivation
  • Multidrug resistance phenotypes and genotypes
  • Rapid resistance detection techniques and molecular diagnostics
Typical Fit Example

"Characterization of novel beta-lactamase variants in carbapenem-resistant Enterobacteriaceae: structural analysis and kinetic properties"

Antibiotic Biosynthesis & Chemistry

  • Biosynthetic pathways and gene clusters
  • Enzymatic mechanisms in antibiotic production
  • Natural product discovery from microbial sources
  • Chemical synthesis and semi-synthesis of antibiotics
  • Structure-activity relationships (SAR)
  • Bioconversion and biotransformation processes
Typical Fit Example

"Elucidation of the glycopeptide antibiotic biosynthetic pathway in Amycolatopsis orientalis using CRISPR-Cas9 gene editing"

Molecular Mechanisms of Action

  • Target identification and validation
  • Protein-antibiotic interactions and binding kinetics
  • Cell wall synthesis inhibition mechanisms
  • Ribosomal targeting and protein synthesis disruption
  • DNA/RNA synthesis interference
  • Membrane disruption and bactericidal mechanisms
Typical Fit Example

"Cryo-EM structure of the ribosome bound to novel oxazolidinone derivatives reveals unique binding mode and resistance implications"

Microbial Genetics & Genomics

  • Comparative genomics of antibiotic-producing organisms
  • Functional genomics and transcriptomics
  • Metagenomics for antibiotic discovery
  • CRISPR-based genetic manipulation
  • Evolutionary dynamics of resistance genes
  • Genome mining for biosynthetic gene clusters
Typical Fit Example

"Pan-genome analysis of Streptomyces species reveals cryptic biosynthetic pathways for novel polyketide antibiotics"

Secondary Focus Areas

Pharmacokinetics & Pharmacodynamics

Molecular aspects of antibiotic absorption, distribution, metabolism, and excretion (ADME); PK/PD modeling at the cellular level; drug-drug interactions affecting antibiotic efficacy.

Host-Pathogen Interactions

Bacterial virulence factors; immune evasion mechanisms; biofilm formation and antibiotic tolerance; quorum sensing and its role in resistance; molecular basis of bacterial pathogenesis.

Applied Microbiology

Industrial production optimization; fermentation technology; strain improvement through genetic engineering; downstream processing; quality control methods for antibiotic production.

Proteomics & Metabolomics

Proteomic profiling of antibiotic responses; metabolic pathway analysis; systems biology approaches; mass spectrometry-based identification of resistance markers.

Antimicrobial Agents Spectrum

Antibacterial, antifungal, antiparasitic, and antiprotozoal agents; spectrum of activity determination; cross-resistance patterns; combination therapy at molecular level.

Toxicology & Safety

Molecular toxicology; adverse drug reactions at cellular level; genotoxicity assessment; structure-toxicity relationships; mitochondrial toxicity mechanisms.

Emerging Research Frontiers

Selective Consideration

The following emerging areas are considered on a case-by-case basis. Manuscripts must demonstrate substantial microbiological innovation and undergo additional editorial review to ensure alignment with our core mission.

CRISPR-based antimicrobial development
Phage therapy and phage-antibiotic synergy
Artificial intelligence in antibiotic discovery
Nanotechnology-based delivery systems
Immunomodulators as adjunct therapy
Microbiome-targeted interventions
Antimicrobial peptides and natural antibiotics
Synthetic biology approaches to antibiotic design

Explicitly Out of Scope

We Do Not Consider

  • Clinical Case Reports: Individual patient cases, treatment outcomes, or clinical management strategies without substantial microbiological investigation or mechanistic insight.
  • Prescribing Guidelines & Stewardship Programs: Hospital protocols, antibiotic prescribing practices, empiric therapy recommendations, or antimicrobial stewardship implementation studies focused solely on clinical practice.
  • Epidemiological Surveys: Pure surveillance studies, infection rate monitoring, or epidemiological reports without molecular characterization or mechanistic analysis of resistance.
  • Clinical Trial Reports: Phase I-IV clinical trials, therapeutic efficacy studies, or patient outcome analyses unless accompanied by detailed microbiological and molecular investigations.
  • Vaccine Development: Immunization strategies, vaccine formulations, or immunological responses unless directly related to bacterial virulence mechanisms or antibiotic resistance.
📄

Article Types & Priorities

Priority 1

Fast-Track Review (14-21 days)

Original Research Articles
Systematic Reviews & Meta-Analyses
Methods & Protocols
Genomic Data Reports
Priority 2

Standard Review (28-35 days)

Short Communications
Data Notes
Technical Notes
Perspectives & Commentaries
Rarely Considered

Requires Strong Justification

Opinion Pieces
Editorials
Book Reviews

Editorial Standards & Requirements

Reporting Guidelines

  • STROBE for observational studies
  • PRISMA for systematic reviews
  • ARRIVE for animal research
  • MIAME for microarray experiments
  • MIQE for qPCR studies

Data Transparency

  • Raw data deposition in public repositories
  • Genome sequences in NCBI/EBI databases
  • Protein structures in PDB
  • Plasmid maps and sequences available
  • Code availability for computational studies

Ethics & Compliance

  • Institutional biosafety approval required
  • Ethical approval for human/animal samples
  • Nagoya Protocol compliance for natural products
  • Conflict of interest disclosure
  • Funding source transparency

Preprint Policy

  • Preprints welcomed (bioRxiv, medRxiv)
  • Must disclose preprint DOI at submission
  • No impact on novelty assessment
  • Preprint servers do not constitute prior publication

Decision Metrics & Performance

Time to First Decision
21 days
Acceptance Rate
35%
Time to Publication
45 days
Article Processing
Open Access